• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Italian observational RealFLOT cohort reports long-term outcomes of perioperative FLOT in resectable gastric cancer

by
October 20, 2026
in Cancer
Reading Time: 2 mins read
0
Italian observational RealFLOT cohort reports long-term outcomes of perioperative FLOT in resectable gastric cancer

Real-World Data Confirm FLOT Chemotherapy Works for Resectable Gastric Cancer in Long-Term Italian Study

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A long-term analysis of the multicentre, prospective observational RealFLOT study reports that perioperative FLOT chemotherapy was feasible in 307 patients with resectable gastric or gastroesophageal junction adenocarcinoma treated in Italy. With a median follow-up of 31.2 months, median disease-free survival was 25.5 months and median overall survival was 73.5 months. These findings describe outcomes in the enrolled cohort and do not establish a causal effect of treatment.

The cohort included patients receiving preoperative FLOT, comprising fluorouracil, oxaliplatin and docetaxel. Most enrolled patients had stage III disease (65.1%), a gastric primary tumour (57.0%) or non-intestinal histology (46.6%). Microsatellite instability was detected in 8.8% of cases and HER2 positivity in 13.6% of tested cases. The investigators estimated survival probabilities with the Kaplan–Meier method, compared groups using the log-rank test and calculated hazard ratios with 95% confidence intervals through Cox regression. Endpoints included disease-free survival, overall survival, pathological complete response and major pathological response.

Among patients receiving preoperative FLOT, 177 (57.6%) completed at least four full-dose cycles. Surgery was performed in 283 cases (92.2%), and 221 patients (72.0%) proceeded to postoperative treatment. Preoperative chemotherapy delays and discontinuations occurred in 90 patients (29.3%) and 15 (4.9%), respectively; postoperative delays occurred in 65 (21.2%) and discontinuations in 25 (8.1%). Gastrointestinal toxicity was the most frequent adverse event, affecting 64.8% of patients before surgery and 65.2% afterward. Grade 3–4 gastrointestinal events occurred in 17 patients (5.5%) preoperatively and 24 (10.9%) postoperatively. R0 resection was reported in 261 of 280 evaluable cases (92.9%).

Pathological complete response was achieved in 8.6% of patients and major pathological response in 26.7%. Patients with either response measure had significantly longer disease-free and overall survival in the survival analyses: the reported hazard ratios were 0.22 and 0.16 for pathological complete response and 0.18 and 0.14 for major pathological response, respectively. The abstract reports p-values of 0.001 and 0.004 for the pathological-complete-response comparisons and p-values below 0.001 for the major-pathological-response comparisons. Overall survival was also significantly longer in patients whose tumours had microsatellite instability, with a reported hazard ratio of 0.00 and p=0.029. These findings are prognostic associations within an observational cohort, not evidence that pathology or biomarker status alone caused the survival differences. The study’s prospective, non-randomised design and the stated 31.2-month median follow-up also constrain comparisons and long-term interpretation, while the supplied abstract does not describe adjustment for potential confounding.

Subject of Research: Long-term observational outcomes of perioperative FLOT in resectable gastric or gastroesophageal junction adenocarcinoma

Article Title: Real world outcomes of perioperative FLOT in an Italian cohort of resectable gastric cancer: long term follow-up of prospective observational Real-FLOT study

Article References: Valle, I., Giommoni, E., Rossini, D., Miceli, C. C., Fornaro, L., Iachetta, F., Pozzo, C., Satolli, M. A., Spallanzani, A., Puzzoni, M., Bergamo, F., Sisani, M., Formica, V., Giovanardi, F., Strippoli, A., Prisciandaro, M., Di Donato, S., Caropreso, G., Salani, F., … Antonuzzo, L. (2026). Real world outcomes of perioperative FLOT in an Italian cohort of resectable gastric cancer: long term follow-up of prospective observational Real-FLOT study. BMC Cancer. https://doi.org/10.1186/s12885-026-16985-1

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16985-1

Keywords: RealFLOT, gastric cancer, gastroesophageal junction cancer, perioperative chemotherapy, FLOT regimen, pathological complete response, major pathological response, overall survival, disease-free survival, microsatellite instability, observational study, Real

News Source: Nathaniel Bowman. (October 20, 2026). Italian observational RealFLOT cohort reports long-term outcomes of perioperative FLOT in resectable gastric cancer. Scienmag.

Tags: disease-free survivalFLOT regimengastric cancerGastroesophageal junction cancerMajor pathological responsemicrosatellite instabilityObservational studyoverall survivalPathological Complete Responseperioperative chemotherapyRealRealFLOT
Share12Tweet7Share2ShareShareShare1

Related Posts

Doxorubicin-loaded iron oxide nanoparticles reduce viability in leukaemia cells in laboratory proof of concept

Doxorubicin-loaded iron oxide nanoparticles reduce viability in leukaemia cells in laboratory proof of concept

October 20, 2026
Ethiopian breast cancer tissue study links immune-cell infiltration to subtype and grade

Ethiopian breast cancer tissue study links immune-cell infiltration to subtype and grade

October 20, 2026

Comment Questions Robustness of Deprivation Links in Breast Cancer Genomics

October 20, 2026

Disparities in late-stage cancer diagnosis across a multi-site academic health system

October 20, 2026

POPULAR NEWS

  • European Setina moth barcodes resolve three main lineages but leave species limits uncertain

    European Setina moth barcodes resolve three main lineages but leave species limits uncertain

    29 shares
    Share 12 Tweet 7
  • Controlled robot experiment shows trigger attack and defense for LLM planners

    29 shares
    Share 12 Tweet 7
  • Taxonomic revision of Anthophora subgenus Caranthophora describes new Ethiopian species

    29 shares
    Share 12 Tweet 7
  • Research report: A new species of the genus Boulenophrys ( Anura , Megophryidae ) from western Guangxi, China

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

European Setina moth barcodes resolve three main lineages but leave species limits uncertain

Controlled robot experiment shows trigger attack and defense for LLM planners

Taxonomic revision of Anthophora subgenus Caranthophora describes new Ethiopian species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.